Investors

 

 

The Gene Therapy Boom

Gene therapy is one of the hottest growth areas in biotech with about  $10 -20  Billion invested annually over the last several years.​ Cellastra is targeting unmet needs in Burn Care, Surgery & viral infects such as RSV, Infuenza and COIVID. The Long COVID has been referred to as a $3.5 Trillion challenge (David Cutler, Harvard Economist).

 

 

Dermal Scarring and Serve Pulmary Fibrosis are Global Health Concerns

Severe and cosmetically challenged dermal scarring after surgery is reported in up to one third of Caucasians and up two thirds of Chinese and polynesian populations. After burn injuries, "a global epidemic",  70- 90 % may suffer from  life long severe scarring. Serve pulmary fibrosis can be caused by influenza, RSV or COVID 19 infections. 

​

​The SCARLEXA Gene Therapy applied in the wound area after surgery or burn injuries, switches on the production of natural anti-scarring peptides, which have already been found to be safe and effective in clinical studies to date. Rather than trying to apply topical treatment for weeks or months, one treatment with SCARLEXA turns on the production of the peptide at the site of the injury for many weeks or months.

​

The FIBREXA Gene Therapy inhaled once and programs the lung epithelium to produce ensereptide, a natural peptide, which may help mitigate root causes of tissue damage and scarring during the acute phase of the infection. The vector may also be given as an intramuscular injection, which may enable production of ensereptide for many months and provide system wide protection against infections like Long COVID affecting multiple organs.​

 

Cellastra offers SOLID SCIENCE - NEAR TERM  GROWTH OPPORTUNITY. See contacts information below.

​​